Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CGAS | Q8N884 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 9/20 | 0.32 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913150 | 0.86 | ROCK2 (0.34) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26913132 | 0.86 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26912514 | 0.86 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26913152 | 0.86 | ROCK2 (0.34) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26912169 | 0.83 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL30684137 | 0.83 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26912165 | 0.83 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26912963 | 0.83 | CGAS (0.36) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26913188 | 0.81 | LRRK2 (0.35) | LRRK2CGASROCK2ROCK1CDC42BPB | |
| SCHEMBL26912804 | 0.77 | PGK1 (0.40) | LRRK2CGASROCK2ROCK1CDC42BPB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | LRRK2 73/4885CGAS 1/4885ROCK2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.